A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

NCT02681237 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Cediranib
DRUG: Olaparib

Sponsor

University Health Network, Toronto

Collaborators

[object Object]